

ASX ANNOUNCEMENT

R & D Tax Incentive Receipt

29th December 2020 – Brisbane Australia

Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system and the Enhanced Infusion System technologies, is pleased to announce the receipt of \$649K from the Australian Taxation Office under the Research and Development Incentive related to the financial year to 30th June 2020.

Analytica wish to acknowledge this critical financial support from the Australian Government for innovation investment and the opportunity to lead the world in pelvic floor muscle treatment research and development. For women, worldwide, incontinence is a common, accepted condition due to poor pelvic floor muscles. Clinical trials have shown Analytica's PeriCoach can dramatically reduce incontinence and improve women's lives with simple in home treatment.

This breakthrough technology would not be possible without the Australian Government active support, as a catalyst to new digital medical treatments.

Authorised for release by the Board.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

